Overview and treatment of ibs with predominant constipation in women

Mariel Flanagan, Mikayla Spangler

Research output: Contribution to specialist publicationArticle

Abstract

Irritable bowel syndrome with predominant constipation (IBS-C) is a chronic disorder that primarily affects women. In 2020, the first clinical guideline by the American College of Gastroenterology for the treatment of IBS was published. A variety of nonpharmacologic recommendations for IBS-C include gut-directed psychotherapy, psyllium fiber, peppermint oil, and a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols. Women with IBS-C have four FDA-approved prescription-treatment options including lubiprostone, linaclotide, plecanatide, and tegaserod. Selection of medication therapy may be guided by cost/insurance coverage, adverse-effect profile, and desired frequency of dosing.

Original languageEnglish (US)
Pages26-33
Number of pages8
Volume46
No9
Specialist publicationU.S. Pharmacist
StatePublished - Sep 2021

All Science Journal Classification (ASJC) codes

  • Pharmacy
  • Pharmacology
  • Pharmaceutical Science

Fingerprint

Dive into the research topics of 'Overview and treatment of ibs with predominant constipation in women'. Together they form a unique fingerprint.

Cite this